Key facts
- This page summarizes Christopher I. Wright's Form 3 filing for Wave Life Sciences Ltd. (WVE).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 17 Apr 2026, 21:00.
Christopher I. Wright - 09 Apr 2026 Form 3 Insider Report for Wave Life Sciences Ltd. (WVE)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- WVE
- Reported as of
- 09 Apr 2026
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 17 Apr 2026, 21:00:05 UTC
- Prior SEC filing
- 10 Jun 2025
- Next SEC filing
- 22 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christopher I. Wright
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher I. Wright filed Form 3 for Wave Life Sciences Ltd. (WVE) on 17 Apr 2026.
Change
- Previous filing in this sequence was filed on 10 Jun 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001838503
Primary reporting owner
Wright Christopher I
- Relationship
- Chief Medical Officer
- Address
- C/O WAVE LIFE SCIENCES LTD.,, 733 CONCORD AVE., CAMBRIDGE
- Signature
- /s/ Christopher I. Wright
- Signature date
- 17 Apr 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
WVE
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 45,625
- Date
- 09 Apr 2026
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
WVE
holding
Derivative
Share Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 09 Apr 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 300,000
- Exercise price
- $5.94
- Footnotes
- F2
WVE
holding
Derivative
Share Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 09 Apr 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 273,750
- Exercise price
- $12.75
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Consists of restricted share units (RSUs). Each RSU represent the right to receive one ordinary share upon vesting. The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030, subject to the Reporting Person's continued service through the applicable vesting date.
Footnote F2
The option vests as to 25% of the shares on May 27, 2026, and vests as to an additional 6.25% of the shares quarterly thereafter until May 27, 2029, subject to the Reporting Person's continued service through the applicable vesting date.
Footnote F3
The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030, subject to the Reporting Person's continued service through the applicable vesting date.
SEC remarks
Exhibit 24.1 - Power of Attorney